Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 1st Patient Dosed in PIII for Gilteritinib as Post-HCT AML Maintenance Therapy: Astellas
August 23, 2017
- Takeda Files Japan NDA for Entyvio
August 23, 2017
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
- Japan’s “Advanced Drug” Market Put at 1.4 Trillion Yen in 2016: Fuji Keizai
August 22, 2017
- PII Study Launched for Sanwa Kagaku/Ube’s Pruritus Drug
August 22, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Regeneron Pain Med
August 18, 2017
- Opdivo Gets 4th Indication in Taiwan for Head and Neck Cancer
August 17, 2017
- Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally
August 17, 2017
- Me Pharma to Roll Out Mevalotin, Gaster Generics in February
August 16, 2017
- Arbitration against Chugai Begins over Add’l Actemra Royalty
August 16, 2017
- 5 Diabetes Drugs in Top 10 List in June GP Recollection Ranking: Anterio
August 15, 2017
- Ethical Drug Sales Up 0.4% in June: Crecon
August 14, 2017
- Wholesalers See Lower Price Settlement Rates as Customers’ Business Flounders
August 9, 2017
- Hisamitsu to Form China Subsidiary, Enhance Sales via Direct Route
August 9, 2017
- Fujifilm Kicks Off PI Study on FLT3 Inhibitor in US
August 9, 2017
- Growth of Global Products Outstrips Abilify Drop in Jan.-June: Otsuka
August 9, 2017
- Astellas Looks to Be First to Market in HIF-PH Inhibitor Space
August 8, 2017
- Pharmaceutical Companies Are No Longer Focusing Exclusively on Internal R&D: Oncodesign Exec
August 8, 2017
- New Heart Failure Med Hits Primary Pharmacokinetic Endpoint: Amgen Astellas
August 8, 2017
- Daiichi Sankyo Invests in Osaka Univ. Spin-Off
August 8, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…